NEW YORK, April 12 (GenomeWeb News) - Metabolon has received a Small Business Innovation Research grant for an undisclosed amount from the NIH to study biomarkers for amyotrophic later sclerosis, the company said today.
Metabolon will use its metabolomics platform to test plasma samples obtained from patients to identify ALS biomarkers, the company said in a statement. Metabolon will then compare these biomarkers with those from other motor neuron diseases, and will study how biomarkers for the disease change with its progression.
The grant was awarded by the NIH's National Institute of Environmental Health Sciences, and is the third award for ALS studies Metabolon has received since the beginning of 2004.
In August, Metabolon received a grant from the National Institute of Neurological Disorders and Stroke to study ALS biomarkers in collaboration with Massachusetts General Hospital. In February 2004, the company received an award from the ALS Association.